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Although lactoferrin has many biological functions, the host-protective effects against pathogenic mi-
croorganisms including bacteria, fungi, and viruses are regarded as one of the most important. Here, we
review research on the protective role of lactoferrin administration against common viral infections.
Many studies have shown the in vitro antiviral activity of lactoferrin against viral pathogens that cause
common infections such as the common cold, inﬂuenza, gastroenteritis, summer cold, and herpes, where
lactoferrin inhibits mainly viral attachment to the target cells. Recently, studies indicating the in vivo
protective effects of lactoferrin by oral administration against common viral infections have been
increasing. For instance, norovirus is an extremely important emerging human pathogen that causes a
majority of gastroenteritis outbreaks worldwide that may be a target candidate for lactoferrin. Lacto-
ferrin consumption reduced the incidence of noroviral gastroenteritis in children and a similar effect was
observed in a wide range of ages in a preliminary survey. A recent in vitro study reported that lactoferrin
inhibits both cellular attachment of the murine norovirus, a virus closely-related to the human norovirus,
and viral replication in the cells by inducing antiviral cytokines interferon (IFN)-a/b. Lactoferrin
administration also enhances NK cell activity and Th1 cytokine responses, which lead to protection
against viral infections. In conclusion, lactoferrin consumption may protect the host from viral infections
through inhibiting the attachment of a virus to the cells, replication of the virus in the cells, and
enhancement of systemic immune functions.
© 2014, Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases.
Published by Elsevier Ltd. All rights reserved.1. Introduction
Lactoferrin, an 80-kDa iron-binding glycoprotein of the trans-
ferrin family, is a component of exocrine secretions such as milk
and saliva, and is present in neutrophil granules [1]. Lactoferrin is
thought to play a role in host defense and exhibits a diverse range of
biological activities, including antimicrobial activities, antiviral ac-
tivities, antioxidant activities, immunomodulation, modulation of
cell growth, and binding of several bioactive compounds [2e4]. The
ﬁrst report on the antiviral effect of lactoferrin was in the studies
conducted by Broxmeyer's group in the 1980s. They showed that
lactoferrin affects the myelopoiesis of mice inoculated with a friend
virus complex [5]. Then, they found that ip-injected lactoferrin
improved the survival rate of mice infected with a friend virus
complex [6]. In the 1990s, the target viruses for which lactoferringy Institute, Morinaga Milk
a 252-8583, Japan. Tel.: þ81
. Wakabayashi).
d The Japanese Association for Infectiwas shown to exhibit antiviral activity were propagated to cyto-
megalovirus (CMV), herpes simplex virus (HSV), human immuno-
deﬁciency virus (HIV), hepatitis C virus (HCV), rotavirus, poliovirus
(PV), respiratory syncytial virus (RSV) [7]. The author of this review
article described that the antiviral effect of lactoferrin lies in the
early phase of infection, preventing the entry of a virus into the host
cells, either by blocking cellular receptors, or by direct binding to
the virus particles [7]. In a recent review article by Berlutti, the
hepatitis B virus (HBV), parainﬂuenza virus (PIV), alphavirus,
hantavirus, human papillomavirus (HPV), feline calicivirus (FCV),
adenovirus, enterovirus 71 (EV71), echovirus 6, inﬂuenza A virus,
Japanese encephalitis virus, and tomato yellow leaf curl virus
(TYLCV) were added as newly identiﬁed viruses which are inhibited
by lactoferrin [8]. In this review, the authors described that lacto-
ferrin may exert its antiviral effect not only in the early phase of
surface interaction between virus and cell, but also intracellularly
because the nuclear localization of lactoferrin in different epithelial
human cells has been observed.
Recently investigations to study the effects of orally adminis-
tered lactoferrin against virus infections in animals and humans
have been performed. These studies suggested that lactoferrinous Diseases. Published by Elsevier Ltd. All rights reserved.
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infections. Here, we review the studies regarding common viral
infections including the common cold, inﬂuenza, viral gastroen-
teritis, summer cold, and herpes, both in vitro and in vivo effect by
oral administration, and discuss the prophylactic potential of lac-
toferrin as a food component.
2. Common cold and inﬂuenza
The common cold and inﬂuenza are the most common viral
infections and they occur in the respiratory tract. The in vitro effects
of lactoferrin against viruses causing common infections are sum-
marized in Table 1. Many viruses cause the common cold. Among
common cold viruses, the antiviral activity of lactoferrin is reported
against the respiratory syncytial (RS) virus [9e11] and para-
inﬂuenza virus [12]. The anti-inﬂuenza virus activity of lactoferrin
is also reported against the inﬂuenza A virus H1N1, H3N2, and
H5N1 (avian) [13e16].
Effects of orally administered lactoferrin on common viral in-
fections are summarized in Table 2. A questionnaire survey of adult
women revealed that consumption of lactoferrin-containing tablets
decreases the incidence of common cold-like symptoms and
gastroenteritis symptoms [17]. Another study reported that lacto-
ferrin administration with milk immunoglobulin reduces the inci-
dence of the common cold in humans [18]. On the other hand,
lactoferrin did not show a favorable effect in an RS virus infection
model of mice [19]. In a mouse inﬂuenza virus-infection model,
lactoferrin feeding lowered lung inﬂammatory markers [20]. There
is no report regarding the effects of lactoferrin on inﬂuenza in
humans yet. NK cells recognize and destroy target cells infected by
inﬂuenza or the parainﬂuenza virus [21] and the relationship be-
tween the frequency of the common cold and the activity of NK
cells has been reported [22]. It has been shown that lactoferrin
feeding enhances NK cell activity in patients with adenomatous
colorectal polyps [23] and the NK cell number in mice [24].
Therefore, increased NK cell activity or number by lactoferrin may
mediate at least partly the host protection against the common cold
and inﬂuenza.
3. Viral gastroenteritis
Gastroenteritis caused by rotavirus and norovirus is a major
illness prevalent in winter. Rotavirus causes gastroenteritis only in
children. Norovirus is an extremely important emerging human
pathogen that causes a majority of gastroenteritis outbreaks
worldwide. The in vitro anti-rotavirus effects of lactoferrin have
been reported [25,26] (Table 1). The human norovirus remains
difﬁcult to study, because there is a lack of cell cultures and animal
models. Instead, feline calicivirus and murine norovirus, which can
be cultured and share a number of biochemical properties, similar
genomic organization and primary RNA sequences with human
norovirus, have been used as a virus surrogate to study human
norovirus. A study using feline calicivirus showed that bovine lac-
toferrin inhibits the viral infection of Crandell-Reese feline kidney
cells by binding to the cells and lactoferricin B inhibits the infection
by binding to the virus [27]. Bovine lactoferrin also decreased
murine norovirus infection to murine macrophage cell line
Raw264.7 through inhibition of the initial murine norovirus
attachment to cells and the subsequent interference with murine
norovirus replication [28]. The induction of antiviral cytokine
interferon (IFN)-a/b expression by lactoferrin was involved in in-
hibition of viral replication in the infected cells. This is the ﬁrst
report that shows the inhibition of viral replication in the cells and
the involvement of IFN-a/b in the antiviral effect of lactoferrin. It
has already been reported that oral administration of lactoferrininduces IFN-a/b in the small intestine of mice [24,29]. From these
ﬁndings, IFN-a/b may be a key mediator in the antiviral effects of
orally administered lactoferrin and the deduced antiviral mecha-
nism of lactoferrin was illustrated in Fig. 1.
The effects of the oral administration of lactoferrin against viral
gastroenteritis, where rotavirus or norovirus was identiﬁed as a
pathogen, have been reported (Table 2). In a study of rotaviral
gastroenteritis in children, daily intake of bovine lactoferrin-
containing products ameliorated the severity of the disease,
although there was no signiﬁcant beneﬁt in reducing infection
incidence [30]. The addition of recombinant human lactoferrin and
lysozyme to a rice-based oral rehydration solution had beneﬁcial
effects on children with acute diarrhea in whom rotavirus was
identiﬁed as a pathogen in 18e19% of stool samples [31]. The daily
administration of lactoferrin tablets to children reduced the inci-
dence of noroviral gastroenteritis [32]. Lactoferrin administration
exhibited no decrease in diarrhea incidence, but decreased longi-
tudinal prevalence and severity in children, where norovirus was
isolated as a pathogen in 35% of diarrheal samples [33]. Recently,
we performed a survey on norovirus-like gastroenteritis incidence
in subjects consuming 100 mg lactoferrin-containing products
including yogurt, yogurt drinks, and milk-type drinks [34]. The
results indicated a lower incidence of norovirus-like gastroenteritis
in groups who frequently consumed lactoferrin products compared
with groups who consumed them at a lower frequency (Fig. 2).
Because there is no prophylactic or therapeutic treatment for nor-
oviral gastroenteritis, lactoferrin is a promising candidate to pre-
vent infection and further studies are warranted to establish more
reliable evidence.
4. Summer colds
Summer colds, also called summer minor illnesses, are caused
by adenoviruses and a family of viruses called enteroviruses. These
have a preference for warmer weather. Adenovirus mainly causes
upper and lower respiratory tract infections, but also causes dis-
eases of the intestine, eyes, liver, urinary tract and lymphoid tissue.
Adenovirus is known to cause pharyngoconjunctival fever, also
called pool fever. Runny nose, nasal congestion and postnasal
drainage are complaints associated with both summer and winter
colds. However, enteroviruses may cause more complicated ill-
nesses, which include fever, sore throat, hacking cough, diarrhea,
and skin rash. Enteroviruses, enterovirus 71 and coxsackievirus
A16, are known as common causative viral agents for hand, foot,
and mouth diseases in humans.
Lactoferrin inhibits the cytopathic effect of adenovirus in HEp-
2 cells [35e37], where the effect of bovine lactoferrin is more
potent than that of human lactoferrin (Table 1). On the other hand,
another investigation reported that human lactoferrin promotes
the binding of adenovirus to human corneal epithelial cells and also
infection of the cells by adenovirus [38]. In this experimental sys-
tem, there was no data on bovine lactoferrin. The anti-enteroviral
activities of lactoferrin are indicated in poliovirus, enterovirus 71,
coxsackievirus A16, echovirus 5, and echovirus 6 [39e44].
Remarkably, bovine lactoferrin induced IFN-a expression of human
neuroblastoma cells (SK-N-SH) and inhibited enterovirus 71-
induced interleukin (IL)-6 production [41]. The antiviral activity of
bovine lactoferrin was not obvious in echovirus 9 [40].
Following enterovirus 71 infection, neonatal pups ingesting
transgenic milk expressed recombinant porcine lactoferrin showed
signiﬁcantly higher survival rate and heavier body weight
compared to wild-type mice [45] (Table 2). On the other hand, oral
supplementation of bovine lactoferrin at a dose of 70 mg/day did
not show beneﬁcial effects in the prevention of enterovirus 71 or
rotavirus infection in children [46].
Table 1
In vitro effects of lactoferrin against viruses causing common infections.
Disease virus Lactoferrin
speciesa
Effective dose
(IC50)
Cell type Effect Reference
Common cold
Respiratory syncytial
virus (RSV)
hLF 10e100 mg/ml Human epidermoid carcinoma (HEp-2) Inhibition of virus growth [9]
RSV hLF 100e1000 mg/ml HEp-2 Inhibition of virus growth [10]
RSV hLF 100 mg/ml HEp-2 Reduction of virus entry into cells [11]
Parainﬂuenza virus
type 2 (PIV-2)
bLF Rhesus monkey kidney (LLCMK2) Inhibition of virus entry into cells [12]
Inﬂuenza
Inﬂuenza A virus (H3N2) bLF 0.89 mM MadineDarby canine kidney (MDCK) Inhibition of cytopathic effect [13]
Inﬂuenza A virus (H3N2) Native bLF 0.625 mM MDCK Inhibition of cytopathic effect [14]
Apo-bLF 1.56 mM
Inﬂuenza A virus
(H1N1, H3N2)
bLF 25e250 pM MDCK Inhibition of virus replication [15]
bLF C-lobe 10e50 pM
Avian inﬂuenza
A virus (H5N1)
bLF 40e80 mg/ml MDCK Antiviral activity [16]
Esteriﬁed bLF <20 mg/ml
Viral gastroenteritis
Rotavirus Apo-bLF 29e58 mg/ml Human colon adenocarcinoma (HT-29) Inhibition of cytopathic effect [25]
Fe3þ-bLF 29e58 mg/ml
Rotavirus Apo-bLF 50 mg/ml HT-29 Inhibition of cytopathic effect [26]
Desialylated bLF 12 mg/ml
Feline calicivirus (FCV,
norovirus surrogate)
bLF 1000 mg/ml Crandell-Reese feline kidney (CRFK) Inhibition of cytopathic effect [27]
LFcin B 50e200 mg/ml
Murine norovirus (MNV) bLF 5e15 mg/well Murine macrophage (Raw264.7) Inhibition of cytotoxic damage [28]
Summer cold
Adenovirus bLF 80 mg/ml HEp-2 Inhibition of cytopathic effect [35]
hLF 560 mg/ml
Adenovirus bLF 0.78 mM HEp-2 Inhibition of cytopathic effect [36]
hLF 6.25 mM
LFcin B 6.25 mM
Adenovirus bLF Interaction with viral III and IIIa
structural proteins
[37]
Adenovirus hLF 100 mg/ml Human corneal epithelial (HCE) Promotion of virus binding
and infection of cells
[38]
Poliovirus (PV) bLF 650 mg/ml African green monkey kidney (Vero) Inhibition of cytopathic effect [39]
hLF 370 mg/ml
Enterovirus 71 (EV71) bLF 11e25 mg/ml Human embryonal
rhabdomyosarcoma (RD)
Inhibition of cytopathic effect [40]
hLF 103e185 mg/ml
EV71 bLF 34.5 mg/ml RD and human neuroblastoma (SK-N-SH) Inhibition of infection [41]
Coxsackievirus A16 bLF 9.3 mg/ml Vero Inhibition of cytopathic effect [40]
Echovirus 5 bLF 1000 mg/ml Human colorectal
adenocarcinoma (Caco-2)
Inhibition of virus replication [42]
Digested bLF 1000 mg/ml
Echovirus 6 bLF 12.5 mM Green monkey kidney (GMK) Inhibition of viral infection [43]
bLF N-lobe 12.5 mM
LFcin B 12.5 mM
Echovirus 6 bLF Interaction with viral
capsid proteins
[44]
Echovirus 9 bLF >250 mg/ml Vero Inhibition of cytopathic effect [40]
Herpes
Herpes simplex
virus-1 (HSV-1)
hLF 500 mg/ml Human embryo lung (HEL) Inhibition of viral infection [47]
HSV-1 hLF 1.41 mM Vero Inhibition of cytopathic effect [48]
bLF 0.12 mM
HSV-1 Apo-bLF 28 mg/ml Vero Reduction of infection [49]
Fe3þ-bLF 12 mg/ml
HSV-2 Apo-bLF 31 mg/ml Vero Reduction of infection [49]
Fe3þ-bLF 5 mg/ml
HSV-1 bLF 10 mg/ml Vero Inhibition of cytopathic effect [50]
bLF1-280 25 mg/ml
bLF345-689 320 mg/ml
HSV-1 bLF 10 mg/ml Vero Inhibition of viral antigen synthesis [51]
bLF N-lobe 30 mg/ml
bLF C-lobe 860 mg/ml
HSV-1 bLF 252 mg/ml Vero Inhibition of viral replication [52]
bLF with
glycyrrhizic acid
15 mg/ml
HSV-1, HSV-2 bLF Vero Inhibition of viral cell-to-cell spread [53]
hLF
LFcin B
LFcin H
HSV-1 bLF Vero Inhibition of intracellular
virus trafﬁcking
[54]
LFcin B
HSV-2 bLF 1000 mg/ml GMK Inhibition of viral infection [55]
LFcin B 100 mg/ml
a Lactoferrin species are abbreviated as follows: human lactoferrin (hLF), bovine lactoferrin (bLF), lactoferricin B (LFcin B), and lactoferricin H (LFcin H).
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Table 2
Effects of orally administered lactoferrin on common viral infections.
Disease virusa Lactoferrin
speciesb
Dose, durationc Subject, number Method Effect Reference
Common cold
ND bLF 600 mg LF/body/d or no
administration, 3 m
Human (adult
woman), 398
Questionnaire survey Reduction of common
cold-like symptoms
[17]
ND bLF and
Ig-rich whey
protein
400 mg LF þ 200 mg
Ig/body/d or placebo, 3 m
Human (adult), 105 Double blind randomized
placebo-controlled trial
Reduction of cold incidence [18]
RSV bLF 2 to 10 mg LF/body/d
or PBS, 7 d
Mice, 58 Intranasal virus infection No difference in viral
loads or disease severity
[19]
Inﬂuenza
Inﬂuenza
virus A (H1N1)
bLF 62.5 mg/body/d, 6 d Mice, 40 Intranasal virus infection Reduction of lung
consolidation score and
inﬁltrated leukocytes
[20]
Viral gastroenteritis
Rotavirus bLF 100 mg LF/body/d or no
administration, 3 m
Human (children), 234 Non-randomized
controlled study
Amelioration of severity
of rotaviral gastroenteritis
[30]
Rotavirus and
other pathogens
hLF 50 to 80 mL solution
with 1 g/L hLF and
lysozyme/kg or control
solution, 48 h
Human (children) 140 Randomized,
double-blind controlled
trial
Decrease in duration and
volume of diarrhea, but no
difference in rotaviral incidence
[31]
Norovirus bLF 400 mg LF/body/d or no
administration, 4 m
Human (children), 91 Randomized
controlled study
Reduction of noroviral
gastroenteritis incidence
[32]
Norovirus and
other pathogens
bLF 500 mg LF twice/d
or placebo, 6 m
Human (children) 555 Randomized, double-blind
controlled trial
Reduction of diarrhea longitudinal
prevalence, but no difference
in noroviral incidence
[33]
Norovirus bLF 100 mg LF/body/d
at 1e7 times per w,
one winter season
Human, 461 Questionnaire survey Lower incidence of noroviral
gastroenteritis in frequently
consuming groups
[34]
Summer cold
EV71 pLF Milk of wild type or
pLF-transgenic mice, 3 w
Mice (neonate), 30 Intraperitoneal
virus infection
Increase in survival rate
and body weight
[45]
EV71 and
rotavirus
bLF 70 to 85 mg LF/body/d
or no administration, 15 m
Human (children), 172 Randomized, single
blind trial
No difference in incidence
of enterovirus or rotavirus infection
[46]
Herpes
HSV-1 bLF 1.5% bLF solution in
drinking water, 20 d
Mice, 30 Cutaneous viral
infection
Prevention of body weight loss
and increase in cytokine responses
[56]
a ND indicates that virus species were not determined.
b Lactoferrin species are abbreviated as follows: bovine lactoferrin (bLF), human lactoferrin (hLF), and porcine lactoferrin (pLF).
c Duration is abbreviated as follows: hours (h), days (d), weeks (w), and months (m).
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Herpes simplex virus type 1 and 2 (HSV-1 and HSV-2) establish
life-long latent infections in the host and can re-emerge periodi-
cally throughout life, primarily causing facial and genital herpetic
lesions, respectively. The in vitro anti-herpes activities of lactoferrin
have been studied in HSV-1 [47e54] and HSV-2 [49,53,55]
(Table 1).Fig. 1. Deduced mechanism of antiviral effect of lactoferrin. Lactoferrin (LF) or lacto-
ferricin (LFcin) prevents virus attachment to the target cells by binding to the virus
receptor on the target cells or binding to the virus. In addition, lactoferrin induces IFN
a/b production and thereby inhibits virus replication after entry of the virus into the
cells.The effect of orally administered lactoferrin in HSV infection has
been reported in one study [56] (Table 2). This study indicated that
lactoferrin administration prevents body weight loss and increases
the production of Th1 cytokines, including IFN-g, IL-12, and IL-18,
after HSV-1 cutaneous infection in mice. These enhanced Th1
cytokine responses may help host protection against HSV-1
infection.0
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Fig. 2. Diagnosis of noroviral gastroenteritis in subjects who consumed lactoferrin-
containing products and who visited the clinic. Subjects were divided by frequency
of consumption of lactoferrin-containing products, and by population of diagnosis by
the medical doctor, (not-norovirus, unknown, norovirus-possible, and norovirus-
positive in the testing, are indicated). Proportions of subjects visited the clinic or
diagnosed as norovirus-possible/positive were statistically compared between each
consumption frequency group and the group of 1 time/week consumption, and p-
values were indicated.
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Lactoferrin exhibits inhibitory activities against a wide range of
viruses in vitro. The effects of lactoferrin oral administration have
been studied in various viral infections in animals and humans.
These infections included life-threating chronic hepatitis C [57], but
no signiﬁcant efﬁcacy of lactoferrin was demonstrated in a clinical
study with a relatively large number of patients [58]. On the other
hand, the beneﬁcial effects of lactoferrin have recently been found
in common viral infections including the common cold, inﬂuenza,
viral gastroenteritis, summer cold, and herpes. As lactoferrin is a
food component, it is easily consumed by an individual to prevent
these infections. Although the mechanism of action of lactoferrin
has not been fully elucidated, direct antiviral activities exerted in
the gastro-intestinal tract and systemic immune-modulation seem
to be involved in these effects. Further basic and clinical studies will
clarify the usefulness of lactoferrin in this ﬁeld.Conﬂict of interest
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